SCHEMBL5735611

SCHEMBL5735611

Nc1ccc2cc(C(=O)O)cc(O)c2c1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
PTPN11 Q06124 3/20 0.49
RNASEH1 O60930 1/20 0.49
GPR35 Q9HC97 1/20 0.49
ATG4B Q9Y4P1 1/20 0.49
KDM4E B2RXH2 4/20 0.44
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA7 P43166 3/20 0.44
CA9 Q16790 3/20 0.44
CA14 Q9ULX7 3/20 0.44
MAPT P10636 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
CA3 P07451 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5734772 0.98 KMT2A (0.49) KMT2AMEN1PTPN11RNASEH1GPR35
Hydrochloric Acid SCHEMBL5737488 0.98 KMT2A (0.49) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL342407 0.79 MEN1 (0.59) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL342924 0.78 CA12 (0.50) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL29914372 0.75 CA12 (0.61) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL686591 0.75 CA12 (0.61) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL1403567 0.74 MEN1 (0.82) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL28172287 0.74 KMT2A (0.61) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL1527153 0.74 MEN1 (0.67) KMT2AMEN1PTPN11RNASEH1GPR35
SCHEMBL3389929 0.73 KMT2A (0.66) KMT2AMEN1PTPN11RNASEH1GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116178673-A Process for preparing composite material by vacuum infusion method 镇江利德尔复合材料有限公司 2023-05-30 CN claimed
CN-116178673-A Process for preparing composite material by vacuum infusion method 镇江利德尔复合材料有限公司 2023-05-30 CN disclosed
CN-116178673-A Process for preparing composite material by vacuum infusion method 镇江利德尔复合材料有限公司 2023-05-30 CN disclosed
EP-1244446-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 EP disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO KMT2A 2330/4885MEN1 135/4885PTPN11 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.